Articles On Imagion Biosystems (ASX:IBX)

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Imagion Biosystems: Breakthrough Device By Pitt Street Research An innovative medical device company   Imagion Biosystems ((IBX)) is an Australian medical device company whose MagSense diagnostic imaging technology, currently in early stage...

Interview with Bob Proulx, CEO Imagion Biosystems By Pitt Street Research Imagion Biosystems: Breakthrough imaging technology   We spoke with Bob Proulx, CEO Imagion Biosystems ((IBX)), about Imagion's revolutionary MagSense imaging technol...

ASX code: IBX Market cap: $12.95m Share price: 4c Shares on issue: 323,705,324 Chairman and CEO: Bob Proulx Board*: Bob Proulx, Michael Harsh, Jovanka Naumoska, Bronwyn Le Grice, Mark Van Asten, David Ludvigson *Dr John Hazle resigned in la...

In light of the volatility that has rocked global equities markets including the ASX, Finfeed felt it was timely to assess the damage on a sector by sector basis. What’s more, we have come up with six stocks that appear to have plenty going...

Event: Possible MRI applications for MagSense Finfeed noted this morning that Imagion Biosystems’ (ASX:IBX) anti-HER2 nanoparticles used in Imagion’s MagSenseTM technology, which provide specific targeting of cancerous cells, may also have...

Shares in Imagion Biosystems (ASX:IBX) have increased approximately three-fold since June on the back of significant developments with its early stage cancer detection technologies. However, they could get a further boost on Monday after th...

According to Imagion Biosystems (ASX:IBX) CEO, Robert Proulx, advancements in imaging have been slow, with no real progress made for half a century. Imagion is looking to redress that balance and speaks with Finfeed about the cancer diagnos...

Through the filing of a Pre-Submission with the U.S. Food and Drug Administration (FDA), MedTech company Imagion Biosystems (ASX:IBX) has taken its first step towards gaining approval to commence its first-in-human study into its non-invasi...

Imagion Biosystems (ASX:IBX) says it has filed pre-submission with the US Food and Drug Administration (FDA), the first step in gaining approval to commence its first-in-human study.

Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe...

Imagion Biosystems (ASX:IBX) has received notification from the FDA's Center for Devices and Radiological Health (CDRH) that its MagSense System and Test for staging HER2 breast cancer has qualified for and been granted designation...

At Stockhead, we tend to judge a company’s size by its market capitalisation. But a company’s enterprise value may be substantially greater – is this good or bad? In short, it depends. Using a base of $500 million, Stockhead has recapped s...

The MagSense test aims to eliminate the unnecessary surgeries and concomitant morbidity resulting from the standard of care biopsy procedure.

Medical tech company Imagion Biosystems (ASX: IBX) has scored a key breakthrough in the development of its breast cancer-detection treatment. The company’s MagSense technology is an upgrade on existing diagnostic imaging uses tiny nanoparti...

Imagion Biosystems (ASX: IBX) has received notification from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer had qualified for...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Want to know when shares are coming out of escrow? We’ve been keeping tabs, so you don’t have to. Every two weeks, Stockhead takes a look at the small cap companies that are releasing shares that have been locked away in escrow. Escrow refe...